No headlines found.
PRNewswire (Wed, 24-Apr 7:00 AM ET)
Alkermes to Report First Quarter Financial Results on May 1, 2024
PRNewswire (Wed, 17-Apr 4:00 PM ET)
PRNewswire (Tue, 9-Apr 7:00 AM ET)
PRNewswire (Mon, 8-Apr 7:00 AM ET)
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
PRNewswire (Thu, 7-Mar 7:00 AM ET)
PRNewswire (Thu, 15-Feb 7:00 AM ET)
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
PRNewswire (Thu, 8-Feb 4:00 PM ET)
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Alkermes PLC - trades on the NASDAQ stock market under the symbol ALKS.
As of April 25, 2024, ALKS stock price declined to $24.41 with 447,043 million shares trading.
ALKS has a beta of 0.46, meaning it tends to be less sensitive to market movements. ALKS has a correlation of 0.02 to the broad based SPY ETF.
ALKS has a market cap of $4.08 billion. This is considered a Mid Cap stock.
Last quarter Alkermes PLC - reported $377 million in Revenue and $.48 earnings per share. This beat revenue expectation by $15 million and missed earnings estimates by -$.03.
In the last 3 years, ALKS stock traded as high as $33.71 and as low as $21.17.
The top ETF exchange traded funds that ALKS belongs to (by Net Assets): IJR, VTI, VB, CALF, IWM.
ALKS has underperformed the market in the last year with a price return of -16.3% while the SPY ETF gained +23.3%. ALKS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.2% and -6.6%, respectively, while the SPY returned +3.8% and -2.3%, respectively.
ALKS support price is $24.11 and resistance is $25.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALKS stock will trade within this expected range on the day.